Investor’s corner

Revenue grew by +31%, exceeding guidance, driven by the strength of international markets, both in direct sales and licensing, alongside acquisitions. The Pharma business reached €175 million (+31%), with ophthalmology establishing itself […]

Strong performance across all business areas enabled the company to close the 2025 financial year with organic revenue above guidance and adjusted EBITDA in line with expectations. The Pharma division achieved double-digit […]

The company exceeds its revenue forecasts for the year as a whole thanks to the strong performance across all business areas The Pharma division posts double-digit growth (+13%) driven by strong performance […]

The transaction reinforces the Group’s new global strategy and boosts ophthalmology as one of its key growth areas. Thanks to this transaction and the acquisition of Edol in March, ophthalmology will account […]

The pharmaceutical business grew by +9% to €269 million, with international markets (+14%) and licenses (+13%) continuing to be the main drivers of growth. The three strategic molecules (Bilastine, Calcifediol and Mesalazine) […]

Shareholder support consolidates the transaction as a transformational step for the company’s strategy The acquisition consolidates Faes Farma as a leading ophthalmology company with one of the most comprehensive offerings in the […]

The Meeting approves the payment of a final dividend of 0.138 euros per share on July 7, for a total dividend of 0.179 euros per share, a pay-out of 51%. All items […]

This acquisition consolidates Faes Farma as a leader in ophthalmology, incorporating a broad portfolio in this key therapeutic area. It enhances the Group’s international expansion, facilitating direct entry into new European markets. […]

Ophthalmology represents a key strategic opportunity for Faes Farma as it is a therapeutic area with expected double-digit growth. This milestone reinforces Faes Farma’s international growth strategy and consolidates its position in […]